Wang Y.-X.,Tongji University |
Chen X.-M.,Tongji University |
Zhu F.-S.,Tongji University |
Han Y.,Medical University of Chinese |
And 4 more authors.
World Chinese Journal of Digestology | Year: 2011
AIM: To evaluate the safety and safety of intravenous nizatidine in the management of peptic ulcer bleeding. METHODS: A muti-center, randomized, parallel-controlled clinical trial was conducted in 205 patients with endoscopically proved peptic ulcer bleeding. The patients were randomly divided into nizatidine group (n = 102) and control group (n = 103). Patients in the nizatidine group were intravenously given nizatidine 0.1 g three times daily for 5 days, while those in the control group were intravenously given famotidine 20 mg twice daily for 5 days. RESULTS: There were 201 cases evaluable for efficacy and safety. The effective rate and response rate were comparable between the nizatidine group and the control group (85.0% vs 82.2%; 99.0% vs 98.0%; both P > 0.05). Major adverse events include leucopenia, slightly elevated transaminase and anaemia. CONCLUSION: Intravenous nizatidine is a safe and effective drug for treatment of peptic ulcer bleeding.